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ABSTRACT Ovarian cancer is a lethal disease. One of the problems faced by paধents with ovarian cancer is the lack of
symptoms in its early stages, which results in it only being detected when it is at an advanced stage. Therefore, there is
an urgent need for biomarkers that can predict ovarian cancer precisely. The purpose of this study was to determine the
expression of microRNA-21 as a predicধve biomarker candidate in both early- and advanced-stage ovarian cancer. This was
a cross-secধonal study using the blood plasma of 21 healthy control subjects and 37 blood plasma samples from paধents
with ovarian cancer. Blood plasmas were collected, from which the RNA was isolated. Based on the RNA, the cDNA was
synthesized and run through qPCR, the results of which were analyzed using the Livak method. The results showed an
upregulaধon of microRNA-21 in the advanced stage by 2.14 fold compared with the early stage, and 6.13 fold compared
with the healthy controls (p < 0.05). The upregulaধon of microRNA-21 in early-stage ovarian cancer was 2.86 fold compared
with the healthy control subjects (p < 0.05). In addiধon, there was an increase in the expression of microRNA-21 in ovarian
cancer by 4.14 fold compared with the healthy controls (p < 0.05). Based on these results, it can be concluded that the
expression of microRNA 21 upregulated with the severity of the disease.
KEYWORDS microRNA-21; minimally invasive; ovarian cancer; predicধve biomarker
1. Introducধon
Ovarian cancer is one of the leading causes of death with
most first detections occurring in its late stages (Cannis-
tra 2004). Only 20% of ovarian cancer patients are diag-
nosed when the cancer has not yet spread into the ovaries.
Conversely, in 80% of cases, the cancer has metastasized,
metastasis that often occurs in the peritoneum (Bast et al.
2009; Cho and Shih 2009). Poor prognosis is associated
with multiple factors in ovarian cancer: weak invasive
minimum detection, early detection tests, the development
of invisible symptoms, and tumor chemoresistance (Qu
et al. 2011). The International Agency for Research on
Cancer (IARC) in GLOBOCAN 2012 stated that the total
cases of ovarian cancer in Indonesia amounted to 10,238
cases, with the age of most patients being around 60–69
years, and 7,075 of the patients dying. Ovarian cancer
was ranked the third incidence in Indonesia, along with
the fifth leading cause of cancer-associated mortality in
Indonesia. This proves that the incidence of ovarian can-
cer is associated with a delay in the early detection process,
and ovarian cancer causes a decrease in the life expectancy
of the community. New biomarkers with high sensitiv-
ity and specificity are needed for the diagnosis and ther-
apeutic targets for ovarian cancer. One of these biomark-
ers that can be used as a candidate for early detection of
ovarian cancer is miRNA (Taylor and Gercel-Taylor 2008;
Resnick et al. 2009).
MicroRNAs are noncoding RNA molecules that have
a nucleotide length of 21–25, and bind to 3 ’UTR in
mRNA where microRNAs inhibit protein translation or
trigger mRNA degradation (Mezzanzanica et al. 2010).
microRNAs can function as both oncomers and tumor sup-
pressors. microRNAs also play an important role in cel-
Indones J Biotechnol 23(1), 2018, 35-39 | DOI 10.22146/ijbiotech.35692
www.jurnal.ugm.ac.id/ijbiotech
Copyright © 2018 THE AUTHOR(S). This arধcle is distributed under a
Creaধve Commons Aħribuধon-ShareAlike 4.0 Internaধonal license.
Karধka et al. Indonesian Journal of Biotechnology 23(1), 2018, 35-39
lular differentiation, cell growth, stress response, and cell
death, viamodulation of the target mRNA transcription ex-
pression (Koutsaki et al. 2014). Specific types of microR-
NAs target specific mRNAs, microRNAs are stable and
are excreted out of cells by vesicles and exosomes and cir-
culate into the bloodstream (Yang et al. 2008; Chao et al.
2014). There are different patterns of miRNA expression
in both the serum and plasma of cancer patients compared
with healthy controls, which means miRNA can be used
as a biomarker candidate to diagnose malignancy (Zhou
et al. 2012; Chen et al. 2013).
Several studies related to miR-21 expression in ovar-
ian cancer, miR-21 were exposed to serum from Epithe-
lial Ovarian Cancer (EOC) patients comparedwith healthy
controls (Resnick et al. 2009), overexpression of miR-21
with exosome isolation in plasma of ovarian cancer pa-
tients compared to controls, i.e. Benign Ovarian Ade-
noma (Taylor and Gercel-Taylor 2008), upregulation of
miR-21 in the serum of EOC tumor-type ovarian cancer
patients was compared to healthy controls (Suryawanshi
et al. 2013). The studies that have been conducted in as-
sociation with the expression of miR-21 in ovarian can-
cer proved to be a change in expression to overexpression
compared with healthy controls. However, the expres-
sion of miR-21 in plasma of ovarian cancer patients with
the population of Indonesia especially Yogyakarta has not
been previously identified. This study aimed to measure
changes in miR-21 expression in the plasma of ovarian
cancer patients compared with healthy controls using a
minimally invasive method.
2. Materials and methods
2.1. Paࣅent samples
A total of 19 early-stage ovarian cancer patients, 18
advanced-stage patients, and 21 healthy control patients
being treated in Sardjito General Hospital, Yogyakarta,
Indonesia, were included in the study during the period
of September 2015 to May 2016. The subjects’ ages
ranged from 21 to 70 years old. Stage breakdown was
n = 17 for stage I, n = 2 for stage II, n = 14 for stage III,
and n = 4 for stage IV. Informed consent was obtained
from each patient prior to sampling. Blood samples up
to 5 mL in volume were drawn from a peripheral venous
puncture prior to surgery. The blood was collected us-
ing an EDTA tube measuring 5 mL. Immediately after
sample collection, the blood samples were centrifuged at
1,500 rpm for 10 min at 4°C. Plasma was transferred into
1.5 mL RNase-free tubes using a tip filter, and then the
plasma was stored at −80°C until further use. Ethical
approval was obtained from the Medical and Health Re-
search Ethics Committee (MHREC), Faculty of Medicine,
Universitas Gadjah Mada-Dr. Sardjito General Hospital
(Ref: KE/FK/085/EC/2015) and all plasma samples were
acquired with the informed consent of the respective indi-
viduals.
2.2. MicroRNA isolaࣅon and real-ࣅme quanࣅtaࣅve
PCR
The plasma sample of −80°C was melted and then cen-
trifuged at 3000 g, for 5 min at 4°C and taken as much as
200 μL. Total RNA was extracted using miRCURY RNA
Isolation Kit-Biofluid kit according to manufacturer’s in-
struction (Exiqon, Denmark). RNA is stored in a refriger-
ator −80°C for reuse.
Immediately done DNA synthesis of RNA was ob-
tained. Making cDNA is done using a Universal cDNA
Synthesis kit according to manufacturer’s instruction (Ex-
iqon, Denmark). The preparation and distribution of the
master mix was done by mixing the 4 μL 5x reaction
buffer, 9 μL Nuclease free water, 2 μL Enzyme mix, and 1
μL Spike in (sp6), up to a total volume of 16 μL reagents
and sprayed with 4 μL RNA samples up to total volume
20 μL per reaction. The reaction mixture was incubated at
42°C for 60 min, inactivated reverse transcriptase at 95°C
for 5 min, and cooling down at 4°C. The cDNA synthesis
results were stored in a refrigerator at −20°C.
Furthermore, cDNA was diluted with RNase-free wa-
ter at a ratio of 1:80, ie 1 μL cDNAwith 80 μL RNase-free
water. Real Time Quantitative PCR using ExiLent SYBR
Green master mix kit according to manufacturer’s instruc-
tion (Exiqon, Denmark). primary set (forward and re-
verse) microRNA, cDNA that has been made before. The
RNA is then preparedmixedmaster mix for the target miR-
16 as the reference gene, miR-21, and 1H2O.Asmany as 5
μl SYBR Green master mix, and 1 μl mixed primary PCR
mix (for each differentiated mixture). 4 μL cDNA coupled
with 6 μLmaster mix. The reaction mixture was incubated
at 95°C for 10 min, followed by 40 cycles of 95°C for 10
s, 60°C for 1 min ramp-rate 1.6°C/s optical read and an-
alyzed melting curve. The result of qRT-PCR duplicate,
and miR-16 was used as the internal control. The rela-
tive miR-21 expression was calculated using the equation
2 DD Ct, the difference between the original copy num-
ber of miR-21 in the ovarian cancer group and that in the
healthy control, −DD Ct = (Ct miR-21  Ct miR-16) of
the ovarian cancer group, −(Ct miR-21   Ct miR-16) of
the healthy control.
2.3. Staࣅsࣅcal analyses
All statistical analyses were carried out using SPSS. p val-
ues < 0.05 were considered statistically significant. Data
were expressed as the mean ± SD. Expression of miR-21
in both early-stage and advanced-stage ovarian cancer was
analyzed using ANOVA and to compare two variables us-
ing the Mann-Whitney test.
3. Results
3.1. miR-21 undergoes upregulaࣅon in plasma sam-
ples of ovarian cancer
The non-parametric Mann-Whitney test was employed to
compare miR-21 expression in patients with ovarian can-
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TABLE 1 Expression of miR-21 in plasma samples of ovarian cancer and healthy control.
Plasma samples miRNA targeted Mean (DCq) ± SD DDCq Fold change (2−DDCq)
Ovarian cancer miR-21 as target 0.4078 ± 1.3922
miR-16 as internal control
−2.0512 4.1445
Healthy control miR-21 as target 2.4590 ± 1.6084
miR-16 as internal control
cer and healthy controls. The results showed that miR-21
had a significant upregulation in ovarian cancer patients
(Table 1). MiR-21 expression in the ovarian cancer sam-
ples was upgraded four times when compared with the
control (p < 0.05). The mean ± SD DCq value of miR-
21 was 0.4078 ± 1.3922 in the 37 ovarian cancer samples,
and 2.4590 ± 1.6084 in the healthy control subjects.
3.2. Plasma miR-21 is associated with cancerous ma-
lignancy rates in the FIGO stage
To determine the important role of plasma miR-21 in the
development and progression of ovarian cancer, we ex-
amined the association of miR-21 expression at various
stages of malignancy in ovarian cancer (Table 2). Clas-
sification of cancer based on FIGO stage, i.e. early-stage
ovarian cancer patients (numbering 19 in total) had amean
± SD 0.9421 ± 1.0198, and advanced-stage ovarian cancer
patients (18 in total) had a mean ± SD −0.1561 ± 1.5321.
Based on the results obtained, miR-21 in advanced-stage
ovarian cancer patients experienced a two-fold upregula-
tion compared with early-stage cancer patients (p < 0.05,
ANOVA). Meanwhile, miR-21 in early-stage ovarian can-
cer of plasma undergoes upregulation three tp < 0.05).
The highest increase of expression was found in miR-21
plasma of advanced ovarian cancer when compared with
healthy control that was 6 times (p < 0.05). These results
expand on the current knowledge in cancer research, show-
ing that the expression of miR-21 in plasma will have up-
regulation in accordance with the stage of the malignancy.
There is not only an increase at the advanced stage, but
in the early stage, as well, with plasma miR-21 increasing
three-fold, which suggests that miR-21 can be a promis-
ing biomarker candidate for the early detection of ovarian
cancer.
4. Discussion
Ovarian cancer is one of the most severe forms of cancer
that can cause death and occur only in women. In its early
stages, ovarian cancer does not show specific symptoms
that might encourage patients to undergo an early exam-
ination. In addition, the location of the ovary organs in
the abdominal cavity means that an examination cannot
be done consciously like with breast cancer.
Weak examination using CA 125 biomarkers also
causes a false positive ovarian cancer diagnosis. CA 125
is very weak for specificity (SP) and sensitivity (SN), so it
is not a reliable biomarker in screening in early detection
of ovarian cancer (U.S. Preventive Services Task Force
2004; Coticchia et al. 2008; Rauh-Hain et al. 2011). CA-
125 values in normal serum range from 0–35 U/mL, with
an excess of these values indicating a malignancy or non-
cancerous disease (Bhatt et al. 2010). Based on observa-
tions on patient status in the Medical Record Room of Dr.
Sardjito General Hospital from September 2015 to April
2016, the obtained data revealed that of 52 patients mea-
sured for the number of CA-125, eight patients that had
CA-125 levels <35 U/mL were diagnosed with a tumor,
19 patients that had CA-125 levels >35 U/mL were diag-
nosed with a tumor, and 25 patients with CA-125 levels
>35 U/mL were diagnosed with ovarian cancer (based on
definitive PA results).
TABLE 2 Expression of miR-21 in plasma samples of early and advanced ovarian cancer compared with the healthy controls.
Plasma samples miRNA targeted Mean (DCq) ± SD Remarks DDCq Fold change (2−DDCq)
Early-stage
ovarian cancer
miR-21 as target
miR-16 as internal control
0.9421 ± 1.0198 Advanced-stage ovarian
cancer compared with
early-stage
−1.0982 2.1410
Advanced-
stage ovarian
cancer
miR-21 as target
miR-16 as internal control
−0.1561 ± 1.5321 Advanced-stage ovarian
cancer compared with
healthy control
−2.6151 6.1269
Healthy control miR-21 as target
miR-16 as internal control
2.4590 ± 1.6084 Early-stage ovarian cancer
compared with healthy
control
−1.5169 2.8618
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Research related to miRNA has been widely per-
formed for the purpose of diagnosis and prognosis phys-
iopathologie malignancy. Multiple profiling has indicated
that microRNA expression significantly changes in the de-
velopment of ovarian cancer (Iorio et al. 2007; Nam et al.
2008). The microRNA marker in circulating tumor exo-
somes in ovarian cancer patients demonstrates a high level
of correlation with the expression of microRNA in the pri-
mary tumor (Taylor and Gercel-Taylor 2008).
MicroRNA is contained in small particles and these
particles can protect against microRNA from RNase activ-
ity (Mo et al. 2012). MicroRNA plays an important role in
cellular differentiation, cancer development, angiogenesis,
immune response, cell growth, stress response, and cell
death, via modulation of the target mRNA transcription
expression (Kuehbacher et al. 2008; Davidson-Moncada
et al. 2010; Song et al. 2010; Liu et al. 2011; Koutsaki
et al. 2014).
Research has beenwidely conducted on the expression
of miR-21 in ovarian cancer, whether on ovarian tissue,
serum, or plasma. One study using amalignant and normal
ovarian tissue sample reported an overexpression of miR-
21 in ovarian cancer compared with normal tissue (Iorio
et al. 2007). Taylor and Gercel-Taylor (2008) studies us-
ing serum samples in serous adenocarcinoma patients, and
controls using benign ovaries, the results showed several
upregulations of miR-21, -141, -200a, -200c, -203, -20,
and -214 in ovarian cancer. Xu et al. (2013) also showed
that patients with EOC had significantly increased serum
miR-21 compared with healthy controls, and serum ex-
pression of miR-21 had a correlation with FIGO stage.
The recent used both ovarian cancer plasma and
healthy controls aimed at developing a minimally inva-
sive biomarker. The results showed that plasma miR-21
in ovarian cancer had upregulated four times compared
with the healthy control (p < 0.05, Mann-Whitney test).
Based on the FIGO stage, the expression of miR-21 in-
creased along with the increase in stages. The expres-
sion of miR-21 in early-stage ovarian cancer was upreg-
ulated when compared with the healthy controls (p < 0.05,
ANOVA). An increased expression of miR-21 also oc-
curred in advanced ovarian cancer comparedwith the early
stage. Based on these results, miR-21 can be used as a di-
agnostic biomarker candidate of ovarian cancer as it was
found to undergo significant expression changes in the
early stages of ovarian cancer.
5. Conclusions
This study revealed that the level of miR-21 in the plasma
of patients with ovarian cancer showed an increase, and
can be associated with FIGO stage. Increased miR-21 ex-
pression in malignancy conditions can aid in cancer re-
search, especially in the development of diagnostic and
prognostic biomarkers, and may be targeted for a person-
alized medicine ovarian cancer treatment.
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